Skip to main content
Medical information Clinical review pending

Genetic Testing

MPDU1 Gene Glycosylation Disorder Type 1F Genetic Test

This genetic test identifies mutations in the MPDU1 gene, associated with Glycosylation Disorder Type 1F, a metabolic condition. Using Next Generation Sequencing (NGS), it aids in diagnosing and managing this rare disorder. Confirm with the laboratory before booking.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
Results
Approximately 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required for the blood sample. However, a genetic counseling session prior to testing is recommended to discuss family history and the implications of the test.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the MPDU1 Gene Glycosylation Disorder Type 1F Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Suspected Glycosylation Disorder Type 1F
  • ✓Family history of Glycosylation Disorder Type 1F
  • ✓Unexplained developmental delays or intellectual disabilities
  • ✓Symptoms suggestive of a metabolic disorder
  • ✓Genetic counseling for family planning
  • ✓Confirmation of diagnosis
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in the MPDU1 gene associated with Glycosylation Disorder Type 1F. This information can aid in confirming a diagnosis, understanding the underlying cause of symptoms, guiding treatment decisions, and providing genetic counseling for affected individuals and their families.
The MPDU1 Gene Glycosylation Disorder Type 1F NGS Genetic DNA Test is an advanced diagnostic tool using Next Generation Sequencing (NGS) technology. It identifies genetic mutations linked to glycosylation disorders, which can cause significant metabolic issues. Early detection is important for effective management.

This test specifically analyzes variations in the MPDU1 gene, crucial for the body's glycosylation processes. Detecting mutations in this gene can provide valuable information for diagnosis and potential treatment pathways.

Individuals with a family history of metabolic disorders, those experiencing symptoms like developmental delays or unexplained health issues, or patients referred by a healthcare provider may benefit from this test. It can help confirm a diagnosis, guide clinical decisions, inform family planning, and provide peace of mind.

After the test, you will receive a detailed report. It is crucial to discuss these results with your healthcare provider to understand their implications and determine the appropriate next steps based on your genetic profile.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required for the blood sample. However, a genetic counseling session prior to testing is recommended to discuss family history and the implications of the test.
SampleBlood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
MethodologyNext Generation Sequencing (NGS) of the MPDU1 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific mutations within the MPDU1 gene. It may not detect all possible mutations or other genetic conditions that could cause similar symptoms. A negative result does not completely rule out a glycosylation disorder. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Glycosylation Disorder Type 1F is a rare inherited metabolic disorder caused by mutations in the MPDU1 gene, affecting the body's ability to process sugars (glycosylation).
Individuals with symptoms suggestive of the disorder, a family history of Glycosylation Disorder Type 1F, or those referred by a healthcare provider for genetic evaluation should consider this test.
The test involves analyzing a sample of your blood, extracted DNA, or a blood spot on an FTA card using Next Generation Sequencing (NGS) technology to look for mutations in the MPDU1 gene.
Results are typically available within 3 to 4 weeks. Confirm with the laboratory before booking.
A healthcare provider, ideally a geneticist or metabolic specialist, will interpret the results in the context of your clinical information and family history to determine the diagnosis and discuss management options.
Yes, genetic counseling before and after testing is highly recommended to understand the test, its implications, and the results.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp